title: Pharmacoeconomy of drugs used in the treatment of actinic keratoses.
abstract: Actinic keratosis (AK) represents an emerging issue in the area of skin diseases which undergo high risk for developing squamous cell carcinoma (SCC). Recently, evidence has been accumulated that 3% diclofenac sodium and ingenol mubetate may efficiently counteract the development of progressive AK even if the pharmacoeconomic impact of such a treatment remains poorly defined. With the objective of assessing the efficacy of 3% diclofenac sodium versus ingenol mebutate, a comparative cost-efficacy analysis was performed between both pharmacological treatments. In the present analysis, data of efficacy of clinical studies were combined with information on the quality of life associated with AK lesions based on available literature data. Furthermore, the cost associated with the management of these lesions in Italy has been taken into account. To this purpose, we carried out a literature survey on the clinical and economic data among clinical reports available in Italy based on the assessment of related expenditure of public resources and their relationship with the subsequent health benefits.
authors.affiliation: Department of Health Sciences, University of Catanzaro "Magna Graecia", Italy steven.nistico@gmail.com.
authors.forename: S
authors.initials: S
authors.lastname: Nisticò
authors.affiliation: Interregional Research Center for Food Safety & Health, Department of Health Sciences, University of Catanzaro "Magna Graecia", Italy.
authors.forename: V
authors.initials: V
authors.lastname: Torchia
authors.affiliation: Interregional Research Center for Food Safety & Health, Department of Health Sciences, University of Catanzaro "Magna Graecia", Italy.
authors.forename: M
authors.initials: M
authors.lastname: Gliozzi
authors.affiliation: Department of Health Sciences, University of Catanzaro "Magna Graecia", Italy.
authors.forename: U
authors.initials: U
authors.lastname: Bottoni
authors.affiliation: Department of Health Sciences, University of Catanzaro "Magna Graecia", Italy.
authors.forename: E
authors.initials: E
authors.lastname: Del Duca
authors.affiliation: School of Pharmacy and Nutraceuticals, University of Catanzaro "Magna Graecia", Italy.
authors.forename: C
authors.initials: C
authors.lastname: Muscoli
mesh_terms: D003362:Cost-Benefit Analysis; D004008:Diclofenac / Q000627:therapeutic use*; D004224:Diterpenes / Q000627:therapeutic use*; D006801:Humans; D007558:Italy; D055623:Keratosis, Actinic / Q000188:drug therapy*; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: C486592:3-ingenyl angelate; D004224:Diterpenes; D004008:Diclofenac
keywords: actinic keratosis; cost-efficacy analysis; diclofenac sodium; ingenol mebutate